Chaired by Nobel laureate Phillip A. Sharp, PhD, SU2C’s Scientific Advisory Committee is comprised of highly accomplished researchers, physicians and patient advocates.
Chaired by Nobel laureate Phillip A. Sharp, PhD, SU2C’s Scientific Advisory Committee is comprised of highly accomplished researchers, physicians and patient advocates.
Institute Professor
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Professor Emerita, Department of Biochemistry and Biophysics
University of California San Francisco
Director, Hollings Cancer Center
Dean, College of Medicine
Medical University of South Carolina
Director, Osteosarcoma Institute
Adjunct Clinical Professor of Pediatrics
Cancer and Blood Disease Institute
CHLA, Keck School of Medicine,
University of Southern California
Professor Emeritus
Institute for Advanced Study and
Cancer Institute of New Jersey
Director, Sidney Kimmel Comprehensive
Cancer Center
Johns Hopkins University
Chief Medical Officer, Bolt Biotherapeutics
Professor of Medicine, Mayo Clinic
Lisa K. Simmons Distinguished Chair in
Comprehensive Oncology
UT Southwestern Harold C. Simmons
Cancer Center
Director of the Institute of Translational Genomics
Keck School of Medicine of University
of Southern California
Global Head of External Innovation
Janssen, Pharmaceutical Companies of Johnson & Johnson
Sidney Farber Professor of Medicine,
Harvard Medical School
Dana-Farber Cancer Institute
Chief, Laboratory of Genome Integrity
NIH Distinguished Investigator
Center for Cancer Research National
Cancer Institute
Chief Executive Officer,
Engineering Health (EnHealth)
Executive Dean
Texas A&M University
George Fabyan Professor
of Comparative Pathology
Co-Director, Harvard Institute of
Translational Immunology
Co-Director, Evergrande Center for
Immunologic Diseases Harvard Medical School
Institute Professor
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Lisa K. Simmons Distinguished Chair in
Comprehensive Oncology
UT Southwestern Harold C. Simmons
Cancer Center
Emily Herrmann Chair in Cancer Research
and Director
Methodist Cancer Center at Houston
Methodist Hospital
Chief Medical Officer, Bolt Biotherapeutics
Professor of Medicine, Mayo Clinic
Director of the Institute for Translational Genomics
Keck School of Medicine of University
of Southern California
Professor and Research Division Chief,
Department of Family Medicine
and Community Health
Rutgers Robert Wood Johnson Medical School
Vice Chair for Research and Professor,
Department of Population and Public Health Sciences
Associate Director for Cancer Equity
Norris Comprehensive Cancer Center
University of Southern California
Deputy Director
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Institute Professor
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Director, Osteosarcoma Institute
Adjunct Clinical Professor of Pediatrics
Cancer and Blood Disease Institute
CHLA, Keck School of Medicine,
University of Southern California
Director, Sidney Kimmel Comprehensive
Cancer Center
Johns Hopkins University
President, R&D (Retired)
Biogen Inc.
Senior Scientist
Princess Margaret Cancer Centre
Institute Professor
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Fuller-American Cancer Society Professor of Radiation Oncology
Harvard Medical School
Director of the Center for DNA Damage and Repair and
Director of the Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Chief Medical Officer
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Vice Chair
Department of Pediatric Oncology
Dana-Farber Cancer Institute
Director, Hollings Cancer Center
Dean, College of Medicine
Medical University of South Carolina
SU2C’s scientists are the most capable, passionate and dedicated in their respective fields. This group of extraordinary individuals is constantly pushing towards progress, thus allowing for revolutionary discoveries. SU2C is supported by a team of more than 1,900 scientists from more than 210 prestigious medical and educational institutions that are united under one cause to end cancer as we know it.
We enable the best and brightest in the cancer research community to work together within Dream Teams, Translational Teams, Convergence Teams, Catalyst™ Teams, and through Innovative Research Grants.
The work of Stand Up To Cancer is supported by its scientific partner, the American Association for Cancer Research. The AACR, in collaboration with SU2C’s Scientific Advisory Committee, conducts highly involved review processes to identify which of the top research proposals have the potential to make a significant impact in the cancer space.